Potential SCD Therapies by GBT Safe in Healthy People, Trials Show

Potential SCD Therapies by GBT Safe in Healthy People, Trials Show

313239

Potential SCD Therapies by GBT Safe in Healthy People, Trials Show

GBT601 and inclacumab, experimental therapies from Global Blood Therapeutics (GBT) for sickle cell disease (SCD) and associated vaso-occlusive crises (VOCs), were generally safe and showed signs of biological activity in healthy volunteers, according to data from Phase 1 clinical trials. These findings will be presented by GBT through two posters at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, to be held Dec. 11–14 in Georgia and online. “We’re very excited to present…

You must be logged in to read/download the full post.